China’s anti-COVID-19 drug enters late-stage human trial
22 November 2021. A Chinese antiviral medicine for COVID-19, called JS016, has commenced phase-3 clinical trials overseas. The drug has been used for emergency treatment in 15 countries, and more than 500,000 doses have been sent overseas.https://www.chinadaily.com.cn/a/202111/22/WS619b3d10a310cdd39bc76c0a.html